Ravulizumab for treating atypical haemolytic uraemic syndrome

Equality Impact Assessment (Guidance development) (PDF 143 KB)

Final draft guidance

Final appraisal document (PDF 227 KB)

Public committee slides (PDF 886 KB)

Committee papers (PDF 4.3 MB)

Final scope (PDF 169 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 314 KB)

Final stakeholder list (PDF 187 KB)

Equality impact assessment (Scoping) (PDF 125 KB)

Draft scope pre referral (PDF 181 KB)

Draft matrix pre referral (PDF 187 KB)

Draft scope pre referral (PDF 205 KB)

Draft matrix pre referral (PDF 208 KB)